Skip to main content
Clinical Trials/NCT02969642
NCT02969642UnknownPhase 2

A Single-center, Sham-controlled, Single Attack Study of Laser Therapy to the Sphenopalatine Ganglion (SPG) in the Acute Treatment of Migraine

The San Francisco Clinical Research Center1 site in 1 country60 target enrollmentStarted: March 1, 2016Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 2
Sponsor
Enrollment
60
Locations
1
Primary Endpoint
Differences between treatment groups in pain free rates at 2 hours post treatment.

Study Overview

Brief Summary

This study evaluates the treatment of migraine pain using low energy laser light to quench migraine signals issuing from the sphenopalatine ganglion (SPG).

Detailed Description

This is a double blinded, two arm study, comprising a sham laser and a treatment laser. The sham laser emits approximately 1/1000 the energy of the treatment laser.

It is presumed that pain relief from the treatment laser is achieved by exhausting the release of neurotransmitters from the SPG following laser stimulation. Subjects will be treated and subsequently queried at time intervals for their self-assessment of pain score (VAS). The time intervals include queries at 5 minutes through 2 hours post treatment. Subjects will be further contacted 24 hours and one month post treatment. Adverse events will be monitored and recorded.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •male or female
  • •aged 18 or older;
  • •subject diagnosed with migraine according to The International Classification of Headache Disorders- Version 3;
  • •1-20 headache days per month;
  • •history of at least moderate pain if migraine left untreated.

Exclusion Criteria

  • •headache on greater than 25 days/month on average for preceding 3 months;
  • •headache on greater than 25 days in present month;
  • •headache attributed to: head or neck trauma, cluster headache, specific migraine variants such as basilar artery, ophthalmoplegic, hemiplegic, etc;
  • •women of child bearing age not using acceptable method of contraception;
  • •pregnant or nursing women;
  • •history of malignancy of any organ
  • •uncontrolled: hypertension, severe psychiatric disorders, or known use of narcotics, analgesic or alcohol abuse;
  • •light sensitivity;
  • •retinal disease;
  • •intranasal pathology.

Arms & Interventions

Sham

Sham Comparator

Sham low energy laser using approximately 1/1000 th energy of treatment laser.

Intervention: Argus Migraine Treatment device (Device)

Treatment

Active Comparator

Treatment laser.

Intervention: Argus Migraine Treatment device (Device)

Outcomes

Primary Outcomes

Differences between treatment groups in pain free rates at 2 hours post treatment.

Time Frame: 2 hours post treatment

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
The San Francisco Clinical Research Center
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials